Company Ticker News February 10, 2022Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis 0 0 Share
Press Release February 10, 2022FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis 0 0 Share
Press Release February 10, 2022FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis 0 0 Share
Company Ticker News February 4, 2022Top- and Bottom-Line Beat Gives Regeneron Stock a Boost 0 0 Share
Company Ticker News February 4, 2022Top- and Bottom-Line Beat Gives Regeneron Stock a Boost 0 0 Share
Company Ticker News February 4, 2022Regeneron (REGN) Q4 Earnings and Revenues Top Estimates 0 0 Share
Company Ticker News February 4, 2022Regeneron's Q4 Sales, Profits More Than Double With Boost From COVID-19 Treatment Sales 0 0 Share
Company Ticker News February 4, 2022Regeneron shares up premarket after Q4 revenue doubles and blows past estimates 0 0 Share
Company Ticker News February 4, 2022Regeneron quarterly profit nearly doubles on robust sales of COVID-19 therapy 0 0 Share
